SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MGI Pharma MOGN New patents, anti cancer
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: WTDEC who wrote (878)3/31/1998 7:52:00 PM
From: Russian Bear  Read Replies (1) of 1826
 
Thanks for the heads-up, Walter. The study you cite sounds like a Phase II (50 patients, efficacy.) I think you are correct: approval for this drug -- for this indication -- is still a distant prospect. However, it is noteworthy that Ethyol is already on the market for another indication. This could, theoretically, lead to off-label use (something that recently got much easier to promote, if I am not mistaken.)

I wonder how aggressive AZA will be in pursuing off-label use? Sjogren's Syndrome remains the big prize in this segment, and as we know, SS is severely under-diagnosed. If for no other reason than that, it may not be quite as easy (i.e. cost effective) as it first seems to promote Ethyol off-label. In an extreme scenario, it may even *help* Salagen sales, by expanding the entire saliva market (that is a stretch, granted.)

Does anyone have any thoughts?

Regards,
RB
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News